The development of novel and selective p56lck tyrosine kinase inhibitors.
Early T-cell receptor mediated signal transduction involves the activation of several tyrosine protein kinases. One of these tyrosine kinases, p56lck, is expressed primarily in T-cells and Natural Killer (NK) cells and has been shown to be critical for their proliferative and effector functions. Indandiones have been identified as a potent and selective chemical class that inhibits p56lck.
Bullington
J L
JL
R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
Cameron
J C
JC
Davis
J E
JE
Dodd
J H
JH
Harris
C A
CA
Henry
J R
JR
Pellegrino-Gensey
J L
JL
Rupert
K C
KC
Siekierka
J J
JJ
D000081247:CSK Tyrosine-Protein Kinase; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D007189:Indans / Q000737:chemistry / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000201:enzymology; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000037:antagonists & inhibitors*; D008956:Models, Chemical; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000201:enzymology; D019061:src-Family Kinases
D004791:Enzyme Inhibitors; D007189:Indans; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck); D019061:src-Family Kinases; D017868:Cyclic AMP-Dependent Protein Kinases